Tag: immunotherapy

Liver Cancer Monotherapy Indication for Nivolumab Withdrawn

The indication for nivolumab (Opdivo) as monotherapy for hepatocellular carcinoma (HCC) for patients previously treated with sorafenib has been voluntarily withdrawn by the manufacturer, Bristol-Myers...

Monkeys May Lead the Way for Immunotherapy HIV Cure

A small study conducted in rhesus macaques found a 10-fold reduction in HIV viral load when the monkeys received immunotherapy to block programmed cell death...

Tislelizumab Benefit in HCC Undimmed by Prior Therapies

With the novel immunotherapy tislelizumab, durable responses are achieved for patients with advanced hepatocellular carcinoma (HCC), regardless of the number of prior lines of therapy,...

EC Approves Cemiplimab for Advanced or Metastatic BCC

The European Commission (EC) has approved cemiplimab (Libtayo) for the treatment of adults with locally advanced or metastatic basal cell carcinoma (BCC) who progressed on —...

Immunotherapy Likely New Standard in Advanced Esophageal Cancer

Nivolumab (Opdivo) plus chemotherapy and nivolumab plus ipilimumab (Yervoy) were superior to standard chemotherapy in improving overall survival in patients with advanced esophageal squamous cell...

Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU

Combination therapy with the immunotherapies nivolumab (Opdivo) and ipilimumab (Yervoy) is now approved in the European Union for the first-line treatment of adults with unresectable...

FDA OKs First Targeted Therapy for Subset of Patients With NSCLC

The US Food and Drug Administration (FDA) today granted an accelerated approval for amivantamab (Rybrevant) as the first targeted treatment for patients with non–small cell...

Immunotherapy Drug Fights Early-Stage Lung Cancer

By Dennis Thompson HealthDay Reporter THURSDAY, May 20, 2021 (HealthDay News) — An immunotherapy drug is the first to significantly reduce the risk of cancer...

FDA Expands Use of SLIT Pollen Allergy Treatment to Children

The US Food and Drug Administration (FDA) has approved a new indication for ALK’s under-the-tongue immunotherapy tablet Ragwitek (Ambrosia artemisiifolia) to treat ragweed pollen-induced hay...

Made-to-Order TILs Effective Against Metastatic Melanoma

In just over one third of patients with metastatic melanoma who had experienced disease progression while receiving multiple prior lines of therapy, including immunotherapy and...

Negative Results When Immunotherapy Was Added Onto Radiation

The early halt of a phase 3 trial of avelumab (Bavencio) plus chemoradiotherapy for the treatment of squamous cell head and neck cancer raises a...

Chronic Immune-Related Adverse Events Likely Common After Anti-PD-1 Therapy for Melanoma

NEW YORK (Reuters Health) – Chronic immune-related adverse events (irAEs) associated with anti-programmed cell death-1 (PD-1) therapy for melanoma were more common than previously thought...

Peanut Sublingual Immunotherapy Feasible and Effective in Toddlers

Sublingual immunotherapy for the treatment of peanut allergy is safe and effective, even in children as young as age 1 year. In a double-blind, placebo-controlled,...

Bladder Cancer Indication Withdrawn for Durvalumab

After failing to improve overall survival in unresectable metastatic bladder cancer in a phase 3 trial, this indication will be withdrawn in the United States...

Which Patients With Kidney Cancer Are Likely to Respond to ICI?

Several factors associated with a diminished response to immune checkpoint inhibitor (ICI) drugs among patients with metastatic clear cell renal cell carcinoma (ccRCC) have been...

Fecal Transplant Overcomes Resistance to Immunotherapy

For some patients with advanced melanoma whose conditions had stopped responding to immunotherapy, response was restored after treatment with fecal transplants. The material for the...

Gut Microbiome Predicts Nivolumab Efficacy in Gastric Cancer?

Preliminary data suggest that a certain pattern of gut microbes may be useful in predicting which patients with advanced gastric cancer are likely to benefit...

Judge Delays Rule That Cuts Pay for Drugs in Docs’ Offices

The Trump administration has failed to persuade a judge of the need to rush the implementation of major changes in payments for drugs administered in...

Beta-Blocker May Improve Melanoma Treatment Response

Response rates were high without dose-limiting toxicities in a small phase 1 study that evaluated the addition of propranolol to pembrolizumab in treatment-naive patients with...

Pembrolizumab ‘Preferred Choice’ in MSI-H/dMMR Metastatic CRC

Frontline pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) compared with chemotherapy among patients with microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer, according to results from...

Golimumab Preserves Insulin Production in Type 1 Diabetes

The human monoclonal antibody golimumab (Symponi) preserved endogenous insulin secretion in patients with new-onset type 1 diabetes and reduced their exogenous insulin requirements at 1...

Two-Drug Combo Standard of Care in Advanced Endometrial Cancer

Carboplatin plus paclitaxel (TC) should be the global first-line standard treatment for advanced endometrial cancer, new findings suggest. The combination proved to be noninferior to...

FDA-Approved Peanut Immunotherapy Protocol Comes With a Cost

Peanut allergy immunotherapy now comes with approval from the US Food and Drug Administration (FDA), but it also comes with protocols, standards, and paperwork. Whether...

Real-World Results With Checkpoint Inhibitors Inferior to CT Data

Real-world survival outcomes for cancer patients on immune checkpoint inhibitors (ICIs) are inferior to outcomes reported in patients on clinical trials of ICIs, according to research...

FDA OKs Combo Therapy for First-Line Mesothelioma Treatment

The US Food and Drug Administration (FDA) has approved combination nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb) to be used as first-line treatment...